CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00422799
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:58.547847+00:00
Published At: 2018-01-26T00:00:00+00:00
Record Updated At: 2020-10-27
Results Posted At: 2018-01-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Waldenstrom\u0027s Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-10-27"
protocolSection.identificationModule.nctId: "NCT00422799"
protocolSection.identificationModule.officialTitle: "Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom\u0027s Macroglobulinemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-01-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.